BGM and CGM Market Size, Share, Growth, and Industry Analysis, By Type (Continuous Glucose Monitoring (CGM),Blood Glucose Meter (BGM)), By Application (Household,Hospital,Other), Regional Insights and Forecast to 2035

BGM and CGM Market Overview

The global BGM and CGM Market in terms of revenue was estimated to be worth USD 33481.89 Million in 2026 and is poised to reach USD 139659.37 Million by 2035, growing at a CAGR of 17.2% from 2026 to 2035.

The United States BGM and CGM market is experiencing strong growth driven by increasing diabetes prevalence, rising adoption of continuous glucose monitoring technologies, and expanding accessibility of advanced glucose monitoring devices. Over 25 million Americans were using CGM devices by early 2024, reflecting growing preference for real-time glucose tracking and improved diabetes management. Point-of-care glucose testing devices reached approximately 1.05 million units in 2024, supporting continued demand for blood glucose monitoring solutions across healthcare settings. Leading CGM platforms such as Abbott Libre and Dexcom have expanded their user base significantly, strengthening the adoption of digital glucose monitoring technologies.

The U.S. BGM and CGM market is also benefiting from regulatory advancements, technological innovation, and wider availability of consumer-focused monitoring solutions. FDA approvals for non-prescription CGM devices have improved accessibility for nearly 200 million eligible non-diabetic adults, creating new opportunities beyond traditional diabetes care. Increasing integration of wearable technologies, remote patient monitoring, and personalized healthcare solutions is expected to further accelerate adoption, making the United States one of the most advanced and rapidly expanding markets for glucose monitoring systems.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Rising adoption of CGM devices: 23 percent increase in Libre sales year‑on‑year in 2023.
• Major Market Restraint: Only 2.5 percent of eligible patients currently use CGM devices in the US.
• Emerging Trends: Lifestyle CGM uptake among non‑diabetics grew nearly 15 percent annually.
• Regional Leadership: North America leads the BGM and CGM Market with approximately 40% share, followed by Europe with 25%, Asia-Pacific with 20%, and other regions contributing the remaining share.
• Competitive Landscape: Dexcom served just under 3 million users, Abbott had over 6 million users.
• Market Segmentation: CGMs comprised about 40 percent share of devices in key markets.
• Recent Development: FDA cleared Dexcom Stelo and Abbott Lingo in 2024, expanding OTC access for millions.

BGM and CGM Market Latest Trends

Current BGM and CGM Market Trends show that continuous glucose monitoring (CGM) devices reached an estimated global user base of 10 million individuals in 2023, with flash monitoring systems like FreeStyle Libre comprising approximately 6 million users. The BGM and CGM Market Report highlights that new FDA approvals in early 2024 allowed two major products Dexcom’s Stelo and Abbott’s Lingo to enter the over‑the‑counter segment, dramatically expanding the potential audience to over 200 million adults in the USA alone. The BGM and CGM Market Analysis points to a 23 percent year‑on‑year uptick in Libre sales during 2023, signaling strong uptake. Sports and wellness sectors are increasingly adopting CGMs: at least hundreds of elite athletes used CGMs during the Paris 2024 Olympics for metabolic optimization.

The BGM and CGM Market Forecast notes that lifestyle CGM usage is growing nearly 15 percent per year, especially among users on weight‑loss medications. The BGM and CGM Market Insights reveal that Biolinq raised $58 million in 2024 to develop a new CGM with built‑in display using seven microneedles. Non‑invasive CGM systems gained regulatory clearance in parts of Europe in 2023, although adoption remained low. Market trends also show integration of CGM data with sports, nutrition and wellness apps, indicating convergence with wearable and fitness tech segments.

How is technological advancement driving the BGM and CGM Market?

Technological advancements are significantly accelerating the growth of the BGM and CGM Market by improving accuracy, convenience, connectivity, and accessibility of glucose monitoring solutions. Innovations such as wearable continuous glucose monitoring sensors, longer-duration sensors, smartphone integration, cloud-based data sharing, and AI-enabled health analytics are enhancing patient monitoring and treatment management. Advanced CGM systems now provide real-time glucose insights, reducing dependency on traditional finger-stick testing and improving personalized diabetes care. The introduction of over-the-counter CGM devices has further expanded adoption among non-diabetic consumers interested in metabolic health and wellness tracking.

BGM and CGM Market Dynamics

DRIVER

"Rising demand for pharmaceuticals"

The BGM and CGM Market is experiencing strong growth due to increasing demand for advanced glucose monitoring technologies among diabetic and health-conscious populations. The expansion of insulin-dependent and type-2 diabetes management has encouraged adoption of continuous and self-monitoring devices, supported by rising healthcare awareness and improved access to digital health solutions. CGM devices from leading manufacturers are gaining acceptance across homecare, hospitals, and clinical environments due to real-time glucose tracking capabilities.

The growing integration of connected healthcare platforms, remote monitoring, and personalized treatment approaches is further supporting market expansion. Pharmaceutical companies and healthcare providers are increasingly adopting glucose monitoring technologies to improve patient outcomes, enhance disease management, and support preventive care strategies. The rising global diabetes burden and demand for efficient monitoring solutions continue to strengthen opportunities in the BGM and CGM market.

RESTRAINT

"Limited penetration among eligible patients"

Despite increasing awareness and technological improvements, limited adoption among eligible users remains a major challenge for the BGM and CGM Market. High device costs, reimbursement limitations, and lack of awareness among certain patient groups restrict widespread adoption, particularly in developing regions. Many potential users still rely on traditional glucose testing methods due to affordability and accessibility concerns.

Additional challenges include concerns regarding device usage, sensor replacement requirements, smartphone connectivity, and data management complexity. Regulatory requirements and the need for clinical validation also slow market expansion in some regions. These factors create barriers for broader adoption, especially among non-insulin users and cost-sensitive populations.

OPPORTUNITY

"Over ""the ""counter access unlocks non""‑""diabetic consumer use"

The introduction of non-prescription glucose monitoring devices is creating new growth opportunities by expanding access beyond traditional diabetes care. Increased interest in metabolic health, fitness tracking, and preventive wellness is encouraging adoption among non-diabetic consumers. Lifestyle-focused CGM solutions are gaining attention among individuals seeking personalized health insights and improved nutrition management.

Growing diabetes prevalence, rising digital healthcare adoption, and increasing consumer interest in wearable technologies provide significant opportunities for market players. Healthcare providers, wellness companies, and technology developers are exploring new applications in sports, preventive healthcare, and remote patient monitoring. These emerging use cases are expected to broaden the customer base for BGM and CGM solutions.

CHALLENGE

"Technological and regulatory barriers to adoption"

The BGM and CGM Market faces challenges related to device complexity, regulatory approvals, and user acceptance. Many advanced monitoring systems require smartphone connectivity, regular sensor replacement, and proper device management, which may reduce adoption among certain user groups. Accuracy concerns and reliability issues associated with emerging technologies also influence consumer confidence.

Regulatory compliance, data security requirements, and limited competition among major manufacturers create additional challenges for market growth. Healthcare providers must ensure device accuracy, patient safety, and compatibility with existing digital health systems. Addressing affordability, usability, and technological limitations remains essential for wider adoption.

Why is Demand Increasing for the BGM and CGM Market?

Demand for BGM and CGM solutions is increasing due to the rising global prevalence of diabetes, growing awareness of preventive healthcare, and increasing adoption of self-monitoring technologies. More than 400 million people worldwide are affected by diabetes, creating significant demand for reliable glucose monitoring devices across household, hospital, and clinical settings. Patients and healthcare providers are increasingly adopting CGM systems because they provide continuous glucose visibility, support better treatment decisions, and improve long-term disease management outcomes.

BGM and CGM Market Segmentation

The BGM and CGM Market Segmentation divides by type Household, Hospital, Other and by application CGM and BGM. By type, household segment accounts for approximately 60 percent of unit shipments, hospital segment about 30 percent, and other settings 10 percent. By application, CGM devices cover about 40 percent of units globally, while BGM (blood glucose meters) still represent 60 percent of device use in diabetes testing markets, measured in annual meter sales (~200 million units per year). This segmentation indicates BGM remains dominant in sheer units, though CGM is rapidly expanding in healthcare and consumer channels.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Continuous Glucose Monitoring (CGM): The CGM segment is gaining significant momentum due to increasing demand for real-time glucose tracking and improved diabetes management. CGM systems provide continuous insights into glucose fluctuations, helping patients and healthcare providers make informed treatment decisions. Adoption is increasing among insulin users, type-2 diabetes patients, and health-conscious consumers.

Technological advancements such as longer sensor duration, improved accuracy, smartphone integration, and wearable designs are supporting CGM adoption. The expansion of over-the-counter availability and lifestyle monitoring applications is further increasing market opportunities. CGM applications represent approximately 40% of device volumes and remain one of the fastest-growing areas in glucose monitoring.

Blood Glucose Meter (BGM): The BGM segment remains widely used due to affordability, accessibility, and established adoption among diabetes patients. Traditional blood glucose meters continue to serve as an important testing method, particularly in regions where cost considerations influence purchasing decisions. Many users prefer BGM solutions due to their simplicity and availability.

Despite CGM expansion, BGM devices maintain strong demand across household and clinical settings. Frequent testing requirements, lower device costs, and widespread availability support continued usage. The BGM segment accounts for approximately 60% of overall device volumes and remains a dominant component of glucose monitoring markets.

BY APPLICATION

Household Segment: The household segment dominates the BGM and CGM Market with approximately 60% market share, driven by increasing preference for home-based glucose monitoring and self-care solutions. Consumers are increasingly adopting wearable continuous glucose monitoring devices and traditional blood glucose meters for convenient diabetes management, regular tracking, and improved health awareness. The availability of compact, user-friendly devices integrated with mobile applications has encouraged individuals to monitor glucose levels without frequent hospital visits.

Growth in remote patient monitoring, digital healthcare platforms, and personalized wellness solutions is further expanding household adoption. The rising focus on preventive healthcare and metabolic health tracking is also attracting non-diabetic users toward consumer-focused glucose monitoring solutions. Subscription-based models, improved sensor technologies, and increased accessibility are expected to strengthen the household segment’s leading position in the BGM and CGM Market.

Hospital Segment: The hospital segment accounts for approximately 30% market share in the BGM and CGM Market, supported by increasing demand for accurate glucose monitoring in clinical environments. Hospitals, intensive care units, and healthcare facilities utilize BGM and CGM systems for inpatient diabetes management, critical care monitoring, and real-time assessment of patient glucose levels. Advanced monitoring technologies help healthcare professionals improve treatment accuracy and provide timely medical interventions.

The adoption of connected healthcare systems, digital patient monitoring, and chronic disease management programs is driving demand for advanced glucose monitoring solutions in hospitals. Healthcare institutions are increasingly integrating CGM technologies to enhance clinical efficiency, reduce complications, and improve patient outcomes. Growing investments in healthcare infrastructure and increasing diabetes management requirements continue to support the expansion of the hospital segment.

Other Segment: The other segment contributes approximately 10% market share in the BGM and CGM Market, including diagnostic centers, pharmacies, outpatient clinics, sports facilities, research organizations, and wellness applications. Increasing adoption of point-of-care testing and preventive healthcare solutions is expanding the use of glucose monitoring devices beyond traditional household and hospital settings. These applications are gaining popularity due to rising awareness of metabolic health and early disease monitoring.

Technological advancements, improved device accessibility, and growing interest in fitness and wellness tracking are creating new opportunities for this segment. Research institutions and healthcare providers are also adopting glucose monitoring technologies for clinical studies and remote monitoring programs. The expansion of digital health ecosystems and personalized healthcare approaches is expected to support continued growth of the other segment in the coming years.

Which Segment is Growing Faster in the BGM and CGM Market?

The Continuous Glucose Monitoring (CGM) segment is growing faster compared with traditional Blood Glucose Meter (BGM) solutions due to increasing preference for real-time glucose tracking and advanced digital healthcare capabilities. CGM devices are gaining rapid adoption among insulin users, type-2 diabetes patients, and wellness-focused consumers because they provide continuous monitoring, smartphone connectivity, and improved glucose management insights. The expansion of over-the-counter CGM devices is further accelerating adoption among non-diabetic users.

BGM and CGM Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominates the BGM and CGM Market with a 40% share, supported by advanced healthcare infrastructure, strong adoption of digital health technologies, and high awareness of diabetes management solutions. The United States represents the largest contributor due to widespread adoption of CGM devices, increasing availability of consumer-focused monitoring systems, and strong presence of leading companies such as Abbott and Dexcom.

The region benefits from favorable regulatory developments, expanding reimbursement support, and increasing use of remote patient monitoring solutions. Growing demand for wearable glucose monitoring devices, over-the-counter CGM systems, and personalized healthcare technologies continues to strengthen market expansion. Increasing adoption among diabetic and non-diabetic users is expected to maintain North America's leadership position.

EUROPE

Europe accounts for 25% of the global BGM and CGM Market, supported by established healthcare systems, increasing diabetes management programs, and rising adoption of advanced monitoring technologies. Countries such as Germany, the United Kingdom, France, and Italy are major contributors due to strong healthcare infrastructure and increasing demand for connected glucose monitoring solutions.

The region is witnessing growing adoption of CGM and BGM devices through reimbursement programs, clinical applications, and preventive healthcare initiatives. Increasing focus on digital health integration, remote monitoring, and personalized treatment approaches is creating new opportunities for market players. Healthcare providers are increasingly incorporating glucose monitoring technologies into chronic disease management programs.

ASIA-PACIFIC

Asia-Pacific represents 20% of the global BGM and CGM Market and is emerging as a high-growth region due to rising diabetes prevalence, expanding healthcare access, and increasing digital healthcare investments. China, India, Japan, and South Korea are key markets with growing demand for affordable and advanced glucose monitoring solutions.

The region is benefiting from improving healthcare infrastructure, rising consumer awareness, and increasing availability of wearable monitoring devices. Local manufacturing expansion, growing distribution networks, and government initiatives for diabetes care are supporting market development. Increasing adoption across hospitals and households is expected to drive future growth in the region.

MIDDLE EAST & AFRICA

Middle East & Africa accounts for 10% of the global BGM and CGM Market, supported by increasing healthcare investments, rising diabetes cases, and growing awareness of disease monitoring solutions. Countries such as Saudi Arabia, UAE, and South Africa are focusing on improving healthcare access and chronic disease management.

The region is witnessing gradual adoption of digital healthcare technologies, remote monitoring solutions, and advanced glucose monitoring devices. Government healthcare modernization programs and increasing investment in medical infrastructure are creating opportunities for BGM and CGM manufacturers. Improved accessibility and awareness are expected to support regional market expansion.

Rest of World

Rest of World contributes 5% of the global BGM and CGM Market, including Latin America and other emerging economies. Increasing diabetes awareness, improving healthcare facilities, and rising demand for affordable monitoring solutions are supporting market growth in these regions.

Growing investments in healthcare infrastructure, expanding distribution channels, and increasing adoption of digital health technologies are creating new opportunities. Manufacturers are focusing on improving accessibility and developing cost-effective glucose monitoring solutions to address the needs of emerging markets.

Which Region Dominates the BGM and CGM Market?

North America dominates the BGM and CGM Market due to advanced healthcare infrastructure, high diabetes awareness, strong adoption of digital health technologies, and favorable regulatory support. The region accounts for approximately 40% market share, supported by significant adoption of CGM devices in the United States. The presence of leading companies such as Abbott and Dexcom, increasing availability of consumer-focused glucose monitoring systems, and expansion of remote patient monitoring solutions continue to strengthen regional leadership.

List of Top BGM and CGM Companies

• Abbott
• Dexcom
• Ascensia
• I-SENS
• AgaMatrix
• Osang Healthcare
• Roche
• Senseonics Holdings
• ARKRAY
• Terumo
• Omron
• 77 Elektronika
• B.Braun
• Acon
• Yuwell
• Sinocare
• Lifescan
• Medtronic
• Yicheng
• SD Biosensor

Top Two Companies with Highest Market Shares

• Abbott – Over 6 million global users of its FreeStyle Libre CGM system, accounting for more than 50% of the global CGM market share.
• Dexcom – Serves just under 3 million users worldwide, holding approximately 30% of the global CGM market share.

Investment Analysis and Opportunities

Investment Analysis and Opportunities in the BGM and CGM Market Report emphasize capital flows and expansion potential. In 2024, Biolinq secured $58 million in venture funding to develop innovative CGM devices with integrated displays and microneedle arrays. The BGM and CGM Market Insights note that startups and biotech firms attracted significant funding as investors seek to challenge the Abbott‑Dexcom duopoly. In 2024, Biolinq began clinical trials, aiming for FDA submission by end‑year. Institutional investment is drawn by the lifestyle CGM opportunity, where adoption has grown nearly 15 percent annually. OTC approvals expanded the addressable US consumer base to over 200 million non‑diabetic adults. Regional manufacturing expansions such as Ultra human’s Ultra Factory in Bengaluru, growing production to 70 000 devices monthly by 2024 underscore scaling investment.

Investment opportunities include manufacturing capacity expansion across Asia‑Pacific, where over 50 million BGM units are sold annually. Government procurement for hospital CGM systems, particularly in North America (USA hospital installations numbering in millions) and Europe (Germany registers showing 370 000 flash‑users + 96 000 trig users), creates further demand. The BGM and CGM Industry Report highlights unmet needs in non‑invasive detection segments, where CE‑marked systems remain under 1 percent market share, presenting technical R&D investment opportunities. Lastly, integration with health data platforms and sports/wellness apps represents growth potential, as seen in athlete usage at mid‑2024 Olympic training and consumer uptake in lifestyle markets.

New Product Development

New Product Development in the BGM and CGM Market Insights emphasizes device innovation and usability enhancements. Dexcom launched its G7 15‑day sensor, cleared by the FDA in April 2025, permitting longer wear duration and improved convenience. Abbott rolled out two new CGM models Libre Rio for non‑insulin type‑2 users and Lingo for non‑diabetic metabolism tracking in USA in mid‑2024 after UK launch in early 2024; these products use sensor wear durations up to 14 days and subscription pricing in the range of 120‑150 pounds per month. Biolinq’s system under development uses seven silicon microneedles with an onboard color display to deliver glucose status without needing a smartphone. Ultrahuman expanded manufacturing to produce up to 70 000 devices monthly in Bengaluru by 2024.

Non‑invasive CGMs received CE marks in Europe in 2023; though uptake remains under 1 percent, development continues. Dexcom is targeting improved battery life and direct Apple Watch integration its G7 now connects to Apple Watch in the USA. Abbott’s FreeStyle Libre 3, cleared in May 2022, provides one‑hour warm‑up time and accurate measurements without fingerstick calibration. Sensor wear maximized at 14 days, Libre 3 also supports alerts configuration. These developments reflect a push for longer wear, user comfort, non‑invasive detection, smartphone‑free reading and integration with wellness platforms.

Five Recent Developments

• In April 2025, Dexcom obtained FDA clearance for its G7 15‑day sensor, enabling users to wear sensors up to 15 days without replacement.
• In March–June 2024, Abbott received FDA clearance for Libre Rio (for non‑insulin diabetes users) and Lingo (for non‑diabetic metabolic tracking), expanding access to over 200 million US adults.
• In mid‑2024, Biolinq raised $58 million in venture capital to develop a CGM with onboard display using seven microneedles, targeting type‑2 users.
• In 2023, non‑invasive CGM systems received CE marks in Europe, though adoption remained below 1 percent of sensor users.
• In 2024, Ultrahuman expanded its Bengaluru UltraFactory production from 10 000 devices monthly (2022) to a 7× increase, reaching about 70 000 devices monthly.

Report Coverage of BGM and CGM Market

The BGM and CGM Market Report scope includes global and regional market sizing, segmentation by type and application, competitive landscape, and recent developments. Coverage includes global CGM user base metrics (approx. 10 million users in 2023), BGM meter annual shipments (200 million units), and diabetes population figures (400 million individuals in 2024). Included are US‑specific metrics: 6 million Libre users, 3 million Dexcom users, 1.05 million point‑of‑care glucose testing units in 2024, and 25 million eligible diabetics.

The report also covers detailed segmentation: household (60 percent of units), hospital (30 percent), and other (10 percent) channels. Application division between CGM (40 percent units) and BGM (~60 percent units) is provided. Geographic coverage spans North America, Europe, Asia‑Pacific, Middle East & Africa, with share figures (North America ~40 percent CGM users, Europe ~25 percent, APAC ~20 percent, MEA ~15 percent). Company profiles include Abbott (6 million users, >5 

BGM and CGM Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 33481.89 Million in 2026
Market Size Value By	USD 139659.37 Million by 2035
Growth Rate	CAGR of 17.2% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Continuous Glucose Monitoring (CGM) Blood Glucose Meter (BGM) By Application : Household Hospital Other
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample